530 related articles for article (PubMed ID: 28444728)
21. Analysis of the BRAF and MAP2K1 mutations in patients with Langerhans cell histiocytosis in Japan.
Hayase T; Saito S; Shioda Y; Imamura T; Watanabe K; Ohki K; Yoshioka T; Oh Y; Kawahara Y; Niijima H; Imashuku S; Morimoto A
Int J Hematol; 2020 Oct; 112(4):560-567. PubMed ID: 32654047
[TBL] [Abstract][Full Text] [Related]
22. Treatment of Langerhans cell histiocytosis: role of BRAF/MAPK inhibition.
Abla O; Weitzman S
Hematology Am Soc Hematol Educ Program; 2015; 2015():565-70. PubMed ID: 26637773
[TBL] [Abstract][Full Text] [Related]
23. Apparent Lack of
Kemps PG; Zondag TC; Steenwijk EC; Andriessen Q; Borst J; Vloemans S; Roelen DL; Voortman LM; Verdijk RM; van Noesel CJM; Cleven AHG; Hawkins C; Lang V; de Ru AH; Janssen GMC; Haasnoot GW; Franken KLMC; van Eijk R; Solleveld-Westerink N; van Wezel T; Egeler RM; Beishuizen A; van Laar JAM; Abla O; van den Bos C; van Veelen PA; van Halteren AGS
Front Immunol; 2019; 10():3045. PubMed ID: 31998317
[TBL] [Abstract][Full Text] [Related]
24. [Status of Langerhans cell histiocytosis in children and adults].
Kudo K
Rinsho Ketsueki; 2019; 60(9):1308-1316. PubMed ID: 31597857
[TBL] [Abstract][Full Text] [Related]
25. CNS Langerhans cell histiocytosis: Common hematopoietic origin for LCH-associated neurodegeneration and mass lesions.
McClain KL; Picarsic J; Chakraborty R; Zinn D; Lin H; Abhyankar H; Scull B; Shih A; Lim KPH; Eckstein O; Lubega J; Peters TL; Olea W; Burke T; Ahmed N; Hicks MJ; Tran B; Jones J; Dauser R; Jeng M; Baiocchi R; Schiff D; Goldman S; Heym KM; Wilson H; Carcamo B; Kumar A; Rodriguez-Galindo C; Whipple NS; Campbell P; Murdoch G; Kofler J; Heales S; Malone M; Woltjer R; Quinn JF; Orchard P; Kruer MC; Jaffe R; Manz MG; Lira SA; Parsons DW; Merad M; Man TK; Allen CE
Cancer; 2018 Jun; 124(12):2607-2620. PubMed ID: 29624648
[TBL] [Abstract][Full Text] [Related]
26. The Value of BRAF VE1 Immunoexpression in Pediatric Langerhans Cell Histiocytosis.
Phan DAT; Phung GB; Duong TT; Hoang AV; Ngo QD; Trinh DTN; Tran TT
Fetal Pediatr Pathol; 2022 Aug; 41(4):558-567. PubMed ID: 33295826
[No Abstract] [Full Text] [Related]
27. Successful treatment of Langerhans cell histiocytosis in an infant with vemurafenib: a case report and literature review.
Li Q
J Dermatolog Treat; 2023 Dec; 34(1):2279901. PubMed ID: 37941458
[TBL] [Abstract][Full Text] [Related]
28. Pediatric Langerhans cell histiocytosis: the impact of mutational profile on clinical progression and late sequelae.
Nann D; Schneckenburger P; Steinhilber J; Metzler G; Beschorner R; Schwarze CP; Lang P; Handgretinger R; Fend F; Ebinger M; Bonzheim I
Ann Hematol; 2019 Jul; 98(7):1617-1626. PubMed ID: 30923995
[TBL] [Abstract][Full Text] [Related]
29. BRAF-V600E expression in precursor versus differentiated dendritic cells defines clinically distinct LCH risk groups.
Berres ML; Lim KP; Peters T; Price J; Takizawa H; Salmon H; Idoyaga J; Ruzo A; Lupo PJ; Hicks MJ; Shih A; Simko SJ; Abhyankar H; Chakraborty R; Leboeuf M; Beltrão M; Lira SA; Heym KM; Bigley V; Collin M; Manz MG; McClain K; Merad M; Allen CE
J Exp Med; 2014 Apr; 211(4):669-83. PubMed ID: 24638167
[TBL] [Abstract][Full Text] [Related]
30. Cutaneous adverse events in children treated with vemurafenib for refractory BRAF
Tardieu M; Néron A; Duvert-Lehembre S; Amine Larabi I; Barkaoui M; Emile JF; Seigneurin A; Boralevi F; Donadieu J
Pediatr Blood Cancer; 2021 Sep; 68(9):e29140. PubMed ID: 34109735
[TBL] [Abstract][Full Text] [Related]
31. Langerhans cell histiocytosis: A neoplastic disorder driven by Ras-ERK pathway mutations.
Tran G; Huynh TN; Paller AS
J Am Acad Dermatol; 2018 Mar; 78(3):579-590.e4. PubMed ID: 29107340
[TBL] [Abstract][Full Text] [Related]
32. Major response to vemurafenib in patient with severe cutaneous Langerhans cell histiocytosis harboring BRAF V600E mutation.
Charles J; Beani JC; Fiandrino G; Busser B
J Am Acad Dermatol; 2014 Sep; 71(3):e97-9. PubMed ID: 25128147
[No Abstract] [Full Text] [Related]
33. Frequency detection of BRAF V600E mutation in a cohort of pediatric langerhans cell histiocytosis patients by next-generation sequencing.
Feng S; Han L; Yue M; Zhong D; Cao J; Guo Y; Sun Y; Zhang H; Cao Z; Cui X; Liu R
Orphanet J Rare Dis; 2021 Jun; 16(1):272. PubMed ID: 34116682
[TBL] [Abstract][Full Text] [Related]
34. Longitudinal assessment of peripheral blood BRAFV600E levels in patients with Langerhans cell histiocytosis.
Schwentner R; Kolenová A; Jug G; Schnöller T; Ahlmann M; Meister B; Lehrnbecher T; Minkov M; Hutter C
Pediatr Res; 2019 May; 85(6):856-864. PubMed ID: 30474648
[TBL] [Abstract][Full Text] [Related]
35. Co-existence of BRAF V600E-mutated malignant melanoma and BRAF V600E-mutated Langerhans cell histiocytosis: A case report.
Goto K; Yoshikawa S; Kiyohara Y; Kukita Y; Miura K; Oishi T
J Cutan Pathol; 2022 Apr; 49(4):393-398. PubMed ID: 34792818
[TBL] [Abstract][Full Text] [Related]
36. Vemurafenib combined with cladribine and cytarabine results in durable remission of pediatric BRAF V600E-positive LCH.
Evseev D; Osipova D; Kalinina I; Raykina E; Ignatova A; Lyudovskikh E; Baidildina D; Popov A; Zhogov V; Semchenkova A; Litvin E; Kotskaya N; Cherniak E; Voronin K; Burtsev E; Bronin G; Vlasova I; Purbueva B; Fink O; Pristanskova E; Dzhukaeva I; Erega E; Novichkova G; Maschan A; Maschan M
Blood Adv; 2023 Sep; 7(18):5246-5257. PubMed ID: 37216396
[TBL] [Abstract][Full Text] [Related]
37. The use of BRAF V600E mutation-specific immunohistochemistry in pediatric Langerhans cell histiocytosis.
Ballester LY; Cantu MD; Lim KPH; Sarabia SF; Ferguson LS; Renee Webb C; Allen CE; McClain KL; Mohila CA; Punia JN; Roy A; López-Terrada DH; John Hicks M; Fisher KE
Hematol Oncol; 2018 Feb; 36(1):307-315. PubMed ID: 28219109
[TBL] [Abstract][Full Text] [Related]
38. Multisystemic and Multiresistant Langerhans Cell Histiocytosis: A Case Treated With BRAF Inhibitor.
Gandolfi L; Adamo S; Pileri A; Broccoli A; Argnani L; Zinzani PL
J Natl Compr Canc Netw; 2015 Jun; 13(6):715-8. PubMed ID: 26085387
[TBL] [Abstract][Full Text] [Related]
39. Genetic landscape of adult Langerhans cell histiocytosis with lung involvement.
Jouenne F; Chevret S; Bugnet E; Clappier E; Lorillon G; Meignin V; Sadoux A; Cohen S; Haziot A; How-Kit A; Kannengiesser C; Lebbé C; Gossot D; Mourah S; Tazi A
Eur Respir J; 2020 Feb; 55(2):. PubMed ID: 31806714
[TBL] [Abstract][Full Text] [Related]
40. Differentiating skin-limited and multisystem Langerhans cell histiocytosis.
Simko SJ; Garmezy B; Abhyankar H; Lupo PJ; Chakraborty R; Lim KP; Shih A; Hicks MJ; Wright TS; Levy ML; McClain KL; Allen CE
J Pediatr; 2014 Nov; 165(5):990-6. PubMed ID: 25441388
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
